Drug intelligence / Profile preview

Episorb

Development stage: Unknown
Lead developer: Celtic Biotech
Modality: Drug Delivery Systems
Administration: Topical

Overview

**Episorb** is a proprietary drug formulation developed by Celtic Biotech, a subsidiary of Spotlight Innovation, designed to facilitate topical delivery of drugs. It functions as an excipient or carrier system enabling enhanced absorption of active pharmaceutical ingredients through the skin. Limited public data exists on its specific mechanism, active components, indications, or clinical development status, suggesting it is targeted at the compounding pharmacy industry for customized topical formulations rather than standalone therapeutic use.

Beyond the preview

Go deeper on Episorb.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Episorb.

Explore the full profile